LabCorp offers a broad menu of tests to diagnose and monitor patients with colon cancer. To search for information about a specific colon cancer test, please visit our Test Menu.
One of LabCorp’s newest tests for colon cancer patients is the KRAS gene mutation detection test.
KRAS mutations are found in 35% to 45% of patients with colorectal cancer. LabCorp’s KRAS mutation test helps physicians know whether these patients are likely to benefit from therapies such as Erbitux® and Vectibix®. Studies have shown that the normal form of the KRAS gene is associated with response to these therapies, while patients with a mutated KRAS gene are less likely to respond.
Recently, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have recommended that patients with metastatic (advanced) colorectal cancer should receive KRAS mutation testing. Understanding the patient’s likely response to drug therapy is important in the selection of appropriate treatments for individual patients.
If you would like more information on the KRAS gene mutation detection test, please complete the KRAS request form.